Citius Pharmaceuticals Inc. (CTXR)
CTXR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2022-09-30, https://www.sec.gov/Archives/edgar/data/1506251/000121390022082217/0001213900-22-082217-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2022-09-30.
Profile
| Field | Value |
|---|---|
| Ticker | CTXR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001506251 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials · 2022
| Line | Value |
|---|---|
| Revenue | $90K |
| Net income | -$33.6M |
| Operating income | -$33.3M |
| Net margin | -37378.5% |
| Operating margin | -37017.8% |
| Revenue growth | 0.0% |
| Cash | $41.7M |
| Total assets | $114.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 160.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "We will need to raise additional capital in the future to support our operations beyond November 2026, which raises substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying consolidated financial statements are issued. 6 The Company is currently engaged in capital raising initiatives, as well as separate capital raising initiatives through its s" | 10-Q 2026-08-14 |
| Cash and burn | $17.0M cash; operating cash flow -$8.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 27,452,570 (2026-08-13); 17,012,191 a year earlier; 158,857,798 three years earlier. 3y figure adjusted for splits (1-for-25 overall). | Cover page 2026-08-13 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-11-26 | Source 2024-11-26 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-04-24 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-21 |
| Auditor | Wolf & Company, P.C., Boston, Massachusetts, United States | PCAOB Form AP 2026-01-27 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | $1.5M | -$11.9M | -$8.7M | $17.0M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2026 2026-03-31 | $1.7M | -$28.1M | -$1.3M | $4.6M | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q1 2026 2025-12-31 | $3.9M | -$9.4M | -$13.0M | $7.7M | $1.0M | Needs four quarters | 10-Q 2026-02-13 |
| Q4 2025 2025-09-30 | Not filed | -$8.7M | -$11.9M | $4.3M | $1.0M | Needs four quarters | 10-K 2025-12-23 |
| Q3 2025 2025-06-30 | Not filed | -$9.2M | -$5.4M | $6.1M | $1.0M | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2025 2025-03-31 | Not filed | -$11.5M | -$4.5M | $26K | No debt tags | Needs four quarters | 10-Q 2025-05-14 |
| Q1 2025 2024-12-31 | Not filed | -$10.3M | -$4.7M | $1.1M | No debt tags | Needs four quarters | 10-Q 2025-05-14 |
| Q4 2024 2024-09-30 | Not filed | -$11.1M | -$5.9M | $3.3M | No debt tags | Needs four quarters | 10-K 2025-12-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-05-22 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-01-28 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-11-04 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-02-24 |
Source: SEC EDGAR submissions feed, 638 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.8% |
| 1 month | +12.4% |
| 3 months | -27.1% |
| Year to date | -31.1% |
| 1 year | -47.0% |
| From 52-week high | -62.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MCRB | Seres Therapeutics Inc. | $1.41 | +0.71% | $14.4M |
| TVRD | Tvardi Therapeutics Inc. | $1.10 | -6.78% | $14.7M |
| ACTU | Actuate Therapeutics Inc. | $0.2680 | -7.59% | $14.7M |
| PBM | Psyence Biomedical Ltd. Common Shares | $2.83 | -11.56% | $15.0M |
| ALLR | Allarity Therapeutics Inc. | $0.8752 | -8.24% | $13.9M |
| BOLT | Bolt Biotherapeutics Inc. | $5.80 | -4.61% | $15.1M |
| AKTX | Akari Therapeutics plc ADS | $6.51 | -4.26% | $15.1M |
| MRKR | Marker Therapeutics Inc. | $0.8286 | -4.76% | $13.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier